![A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer | NEJM A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1983/nejm_1983.309.issue-15/nejm198310133091503/20130822/images/img_medium/nejm198310133091503_t1.jpeg)
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer | NEJM
![Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics](https://pubs.rsna.org/cms/10.1148/rg.2021210005/asset/images/medium/rg.2021210005.tbl1.png)
Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics
![Ca-125 in Ovarian Cancer: To Test or Not to Test? – Latest and Best Treatments in Oncology & Radiotherapy Ca-125 in Ovarian Cancer: To Test or Not to Test? – Latest and Best Treatments in Oncology & Radiotherapy](https://drbhnglatest.files.wordpress.com/2017/09/screen-shot-2018-06-11-at-10-05-53-pm.png?w=1108)
Ca-125 in Ovarian Cancer: To Test or Not to Test? – Latest and Best Treatments in Oncology & Radiotherapy
![Blood ovarian cancer marker test. CA 125. Uterus, ovary with a tumor. Vector medical illustration. White background. Stock Vector | Adobe Stock Blood ovarian cancer marker test. CA 125. Uterus, ovary with a tumor. Vector medical illustration. White background. Stock Vector | Adobe Stock](https://as2.ftcdn.net/v2/jpg/02/57/87/91/1000_F_257879110_YXeX5zXJVj9dHFHjP6uDWg7AJPUrKkkj.jpg)
Blood ovarian cancer marker test. CA 125. Uterus, ovary with a tumor. Vector medical illustration. White background. Stock Vector | Adobe Stock
![PDF] REVIEW OF CARCINOMA ANTIGEN 125 (CA 125) AS A MARKER OF DISEASE PROGRESSION OR RECURRENCE IN CLINICAL TRIALS | Semantic Scholar PDF] REVIEW OF CARCINOMA ANTIGEN 125 (CA 125) AS A MARKER OF DISEASE PROGRESSION OR RECURRENCE IN CLINICAL TRIALS | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a41774d54ed2429de098b01664d00db2774149da/6-Figure2-1.png)
PDF] REVIEW OF CARCINOMA ANTIGEN 125 (CA 125) AS A MARKER OF DISEASE PROGRESSION OR RECURRENCE IN CLINICAL TRIALS | Semantic Scholar
![Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer - ScienceDirect Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0090825813010147-t1.jpg)